Is Johnson & Johnson (JNJ) Resetting Its Device Business With Two Fresh Moves?

• Johnson & Johnson (NYSE:JNJ) received CE Marking in Europe for its ACUVUE OASYS MAX reusable contact lenses for digital device users.
• Jaguar LAA, Inc. agreed to acquire Johnson & Johnson’s Laminar left atrial appendage closure program assets from its MedTech portfolio.
• The Laminar transfer shifts development of the left atrial appendage closure device to Jaguar LAA, while Johnson & Johnson reallocates resources.
• The ACUVUE OASYS MAX approval and Laminar divestment only capture part of what is changing in Johnson & Johnson’s device arm. We have also spotted 2 other big wins worth knowing about at Johnson & Johnson.

For readers tracking how medical devices intersect with software, algorithms and data, this development sits squarely beside 39 healthcare AI stocks.

Johnson & Johnson, a US-based healthcare group with a reported market value of about $643.6 billion, develops pharmaceuticals, medical devices and consumer health products. The ACUVUE and Laminar moves therefore sit inside a much broader portfolio spanning eye care and cardiovascular treatments.

We've flagged 1 risk for Johnson & Johnson. See which could impact your investment.

Does this Johnson & Johnson device news move the Narrative on MedTech or just tidy it up?

Johnson & Johnson’s Narrative leans on a higher return from next-generation medicines and devices while older products and tariffs pull the other way, so every portfolio tweak inside MedTech matters. The ACUVUE approval and Laminar transfer both test whether management is really concentrating capital where that thesis expects it to show up.

"Ongoing expansion within MedTech, highlighted by strong performance from acquired cardiovascular units Abiomed and Shockwave, as well as developments in robotic surgery, are expected to drive revenue growth and enhance adjusted income margins over time…"

See how the full story points towards a $271 fair value for Johnson & Johnson.

The ACUVUE OASYS MAX CE Marking leans into that MedTech expansion story by giving Johnson & Johnson another product built for heavy digital-device use, where competitors like Alcon and CooperCompanies already focus. It supports the idea that the group is willing to refresh established franchises rather than leaning only on new drugs to carry the Narrative.

The Laminar carve out cuts the other way. Moving left atrial appendage closure into Jaguar LAA trims one more in-house bet in a cardiovascular category that analysts already watch beside Abiomed and Shockwave, while leaving Johnson & Johnson with the broader litigation and tariff risks the Narrative flags in the background.

For investors reading Johnson & Johnson through that lens, the same ACUVUE and Laminar news can either look like disciplined portfolio focus or like stepping back from part of the MedTech upside story.

One big Johnson & Johnson question this article has not answered

Product moves and portfolio shifts tell only part of the story for Johnson & Johnson. There is also an estimate of what the whole enterprise may be worth if you look purely at the cash it produces. Find out exactly what Johnson & Johnson is worth today based on its cash flows.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com